Group 1 - The core point of the article is that Baijin Life Sciences (01466.HK) has completed the conditions precedent of a subscription agreement, with the completion date set for November 28, 2025 [1] - A total of 40 million subscription shares will be issued at a subscription price of HKD 0.48 per share [1] - The total amount raised from the subscription is HKD 19.2 million, with a net amount of approximately HKD 19.1 million after deducting related expenses [1] Group 2 - It is expected that 60% of the net proceeds from the subscription (approximately HKD 11.5 million) will be used to repay bank loans, other borrowings, and other payables [1] - The remaining 40% of the net proceeds (approximately HKD 7.6 million) will be allocated for general operating expenses of the group, including audit and professional fees, salaries, and rent payments [1]
佰金生命科学(01466.HK)完成4000万股配售 筹资1920万港元